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Development of a novel aortic dissection mousemodel
and evaluation of drug efficacy using in-vivo assays
and database analyses
Yuki Izawa-Ishizawaa, Masaki Imanishib, Yoshito Zamamib,c, Hiroki Toyad, Tomoko Nagaod,
Marin Morishitae, Koichi Tsuneyamaf, Yuya Horinouchia, Yoshitaka Kihirag, Kenshi Takechih,
Yasumasa Ikedaa, Koichiro Tsuchiyad, Masanori Yoshizumii, Toshiaki Tamakia,
and Keisuke Ishizawab,c
Objective: Aortic dissection is a life-threatening disease.
At present, the only therapeutic strategies available are
surgery and antihypertensive drugs. Moreover, the
molecular mechanisms underlying the onset of aortic
dissection are still unclear. We established a novel aortic
dissection model in mice using pharmacologically induced
endothelial dysfunction. We then used the Japanese
Adverse Drug Event Report database to investigate the role
of pitavastatin in preventing the onset of aortic dissection.
Methods and results: To induce endothelial dysfunction,
Nv-nitro-L-arginine methyl ester, a nitric oxide synthase
inhibitor, was administered to C57BL/6 mice. Three weeks
later, angiotensin II (Ang II) and b-aminopropionitrile
(BAPN), a lysyl oxidase inhibitor, were administered with
osmotic mini-pumps. False lumen formation was used as
the pathological determinant of aortic dissection. The
incidences of aortic dissection and death from aneurysmal
rupture were significantly higher in the Nv-nitro-L-arginine
methyl ester, Ang II, and BAPN (LAB) group than they
were in the Ang II and BAPN (AB) group.
Pitavastatin was administered orally to LAB mice. It
significantly lowered the incidences of dissection and
rupture. It also decreased inflammation and medial
degradation, both of which were exacerbated in the LAB
group. The Japanese Adverse Drug Event Report database
analysis indicated that there were 113 cases of aortic
dissection out of 95 090 patients (0.12%) not receiving
statins but only six cases out of 16 668 patients receiving
statins (0.04%) (odds ratio: 0.30; P¼0.0043).
Conclusion: Our results suggest that endothelial
dysfunction is associated with the onset of aortic dissection
and pitavastatin can help prevent this condition.
Keywords: angiotensin II, aortic dissection, endothelial
dysfunction, lysyl oxidase inhibitor, nitric oxide synthase
inhibitor, pitavastatin, the Japanese Adverse Drug Event
Report Database
Abbreviations: AB, Ang IIþBAPN treated group; Ang II,
angiotensin II; BAPN, b-aminopropionitrile; CI, confidence
interval; DHE, dihydroethidium; eNOS, endothelial nitric
oxide synthase; EVG, Elastica van Gieson’s; H-LAB, higher
dose (100mg/kg per day) of L-NAME treated LAB group;
JADER, The Japanese Adverse Drug Event Report; LAB,
L-NAMEþAng IIþBAPN treated group; L-LAB, lower dose
(10mg/kg per day) of L-NAME treated LAB group; L-NAME,
Nv-nitro-L-arginine methyl ester; MCP-1, monocyte
chemoattractant protein-1; NO, nitric oxide; NOx, nitrite
derivatives; ROR, reporting odds ratio; VCAM-1, vascular
cell adhesion molecule-1; VE-cadherin, vascular
endothelialcadherin
INTRODUCTION
A
ortic dissection is a severe disease. The aortic wall
separates into two layers at the medial level and
creates a true lumen and a false lumen. In most
cases, its onset and the death that ensues are sudden.
Epidemiological investigations into aortic dissection remain
inadequate. Nevertheless, recent reports have demon-
strated that the actual number of patients with aortic dis-
section is much higher than previously estimated [1] and
continues to rise [2]. However, the only available
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therapeutic strategies for aortic dissection are either surgery
or antihypertensive agents and complete rest. Thus, the
development of effective drugs for the prevention and
treatment of aortic dissection is necessary. Known risk
factors for aortic dissection are male sex, hypertension,
aging, and certain genetic connective tissue disorders [1].
Hypertension and medial fragility have been reported as
the most important pathophysiological conditions contrib-
uting to aortic dissection and aneurysm [3]. The administra-
tion of angiotensin II (Ang II) and b-aminopropionitrile
(BAPN) to mice pharmacologically induces acute aortic
aneurysm by causing hypertension and medial degradation
[4]. However, the actual mechanism underlying the onset of
aortic aneurysm or dissection is still unclear.
Recently, the significance of endothelial dysfunction
during the onset of aortic dissection has been addressed.
Fan et al. [5] demonstrated that cell-specific endothelial
NADPH oxidase (NOX) 2 overexpression increases aortic
dissection susceptibility. Gavazzi et al. [6] also reported that
NOX1 is involved in Ang II-induced aortic dissection.
Clinical studies have shown that endothelial nitric oxide
(NO) synthase (eNOS) gene polymorphism is associated
with aortic dissection [7]. These findings indicate that
endothelial dysfunction may be a prerequisite for the onset
of acute aortic dissection and NOS participates in its path-
ogenesis. Nv-nitro-L-arginine methyl ester (L-NAME), a NOS
inhibitor, is often used to induce endothelial dysfunction
and hypertension in mice [8,9]. In the present study, we
tested the hypothesis that adding L-NAME to Ang II and
BAPN could accelerate the onset of dissection but not
aneurysm.
Statins are 3-hydroxy-3-methylglutaryl-CoA reductase
inhibitors. They are widely used as lipid-lowering agents.
To date,many studies show that, because of their pleiotropic
effects, statins are effective in preventing cardiovascular
diseases. In a previous study, we demonstrated that pita-
vastatin protects the endothelium by increasing eNOS
expression [10]. The effect of statins in delaying the progres-
sion of aortic aneurysm has been suggested based on retro-
spective clinical studies [11]. In the present study, we used
a novel mouse model and data mining techniques to evalu-
ate the efficacy of pitavastatin in reducing the incidence
of aortic dissection related to endothelial dysfunction.
MATERIALS ANDMETHODS
Ethics statement
The current study conformed to the Guide for the Care and
Use of Laboratory Animals [12]. All animal procedures were
performed in accordance with the guidelines of the Animal
Research Committee of the University of Tokushima Grad-
uate School. The protocols were approved by the Tokush-
ima University Institutional Review Board for Animal
Protection.
Reagents
Ang II, BAPN, and L-NAME were purchased from Sigma-
Aldrich Japan (Tokyo, Japan). Pitavastatin was purchased
from Wako Pure Chemical Industries Ltd. (Osaka, Japan).
All other reagents and instruments used in the present study
are commercially available.
Mice and in-vivo experimental strategies
Male C57BL/6J mice (10–12 weeks; 25–30 g) were pur-
chased from CLEA Japan Inc. (Tokyo, Japan). One hundred
and sixty mice were used in all sequential experiments of
this study. This sample size was statistically estimated using
Gpower software (Heinrich-Heine-Universita¨t Du¨sseldorf,
Du¨sseldorf, Germany). The mice were divided into four
different groups, as described below. They were housed in
a temperature-controlled room at 25 8C under a 12-h light/
dark cycle. They had free access to food and water. L-NAME
(10 or 100mg/kg per day) was orally administered in
drinking water from age 7 weeks until the end of the
experiment. Dosages were empirically determined in a
previous study [13]. After 3 weeks, the mice were implanted
dorsally with two subcutaneous osmotic mini-pumps
(Model 1002 Micro-osmotic Pump; Alzet, Cupertino, Cal-
ifornia, USA) to administer Ang II and BAPN. Prior to the
surgery, the mice were anesthetized by intraperitoneal
injection of 100–150mg/kg sodium pentobarbital. Pedal
withdrawal reflex, toe pinch reflex, muscle relaxation, and
respiratory rates were monitored to ensure that the
anesthesia was adequate. The dosage was increased if
the mice moved in response to pain after 30min from
the start of the operation. Control mice were sham-oper-
ated. Ang II dissolved in normal saline was continuously
infused at 1000 ng/kg per day for 1 or 6 weeks either to
perform all assays including tissue histopathology or to
estimate survival rates, respectively. BAPN (150mg/kg per
day) was dissolved in saline and administered by osmotic
mini-pump at the same time as Ang II loading and was
maintained for 1–2 weeks. The groups were designated as
follows:
(1) Control: untreated group
(2) AB: Ang IIþBAPN-treated group
(3) L-LAB: lower L-NAME dose (10mg/kg per day) -
þAng IIþBAPN-treated group
(4) H-LAB: higher L-NAME dose (100mg/kg per day) -
þAng IIþBAPN-treated group
Pitavastatin was administered via feeding needle at the
rate of 3mg/kg per day from age 7 weeks until the end of
the experiment. Dosages were empirically determined in a
previous study [14]. Oral saline was administered to the
control animals.
Systolic blood pressure
SBP was measured in conscious mice by tail-cuff plethys-
mography (BP-98A; Softron, Tokyo, Japan).
Isolation of mouse aortas and measurement of
aortic diameters
At the end of the experiment, the animals were anesthetized
by intraperitoneal sodium pentobarbital injection
(150mg/kg) and euthanized by cervical dislocation.
The whole hearts and aortas were isolated and photo-
graphed under a SZ61 Olympus stereomicroscope (Olym-
pus Corp., Tokyo, Japan). Maximum aortic diameters were
measured with ImageJ v. 1.37 (National Institutes of Health,
Bethesda, Maryland, USA).
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Histology and immunohistochemistry
For the morphometry, the aortas were resected and placed
in 10% buffered formalin. After fixation, the tissues were
embedded in paraffin. Sections (5mm thick) were stained
with hematoxylin/eosin or Elastica van Gieson’s (EVG)
stain. Immunohistochemistry was performed using vascular
cell adhesion molecule-1 (VCAM-1) antibody (1 : 1000 dilu-
tion) and a Vectastain ABC Kit (Funakoshi, Tokyo, Japan).
Measurements were taken with ImageJ v. 1.37 (National
Institutes of Health).
Quantitative reverse transcription-PCR
The mRNA expression levels of CD68, F4/80, TNF-a, and
monocyte chemoattractant protein (MCP)-1 in the aortas
were analyzed by quantitative reverse transcription-PCR as
previously described [15]. Sequences of the amplification
primer pairs are as below (50–30): CD68; forward-
CTTCCCACAGGCAGCACAG, reverse-AATGATGAGAGG-
CAGCAAGAGG, F4/80; forward-CTTGGCTATGGGCTT-
CCAGTC, reverse-GCAAGGAGGACAGAGTTTATCGTG,
TNF-a; forward-CCAGACCCTCACACTCAGATC, reverse-
CACTTGGTGGTTTGCTACGAC, MCP-1; forward-CCCA-
ATGAGTAGGCTGGAGA, reverse-TCTGGACCCATTCCT-
TCTTG.
Nitrite/nitrate (NOx) measurements
The total amounts of NO2 and NO3 in the aortas were
measured by the Griess method using an NO2/NO3 Assay
Kit (Dojindo Laboratories, Kumamoto, Japan). Briefly, the
samples were incubated in equal volumes of Griess reagent
[2% sulfanilamide and 0.1% N-(1-naphthyl)ethylenedi-
amine] for 15min followed by incubation in vanadium(III)
chloride for 5 h. The absorbance was measured at 540 nm
using a FilterMax F3 microplate reader (Molecular Devices,
San Jose, California, USA). Values were calculated using
NO2 and NO3 standards.
Reactive oxygen species detection in the aortas
Dihydroethidium (DHE) (10mmol/l) (Dojindo Laborato-
ries) was used to measure the in-situ production of super-
oxide O2 in cryosections of the mouse aortas as previously
described [15]. The intensity of the fluorescence was ana-
lyzed and quantified with ImageJ v. 1.37 (National Institutes
of Health).
En face immunostaining
After 3 weeks of L-NAME and pitavastatin administration,
the aortas of 10-week mice were subjected to en-face
staining. Briefly, the mice were anesthetized with pento-
barbital and euthanized by opening the thoracic cavity.
The arterial tree was perfused with heparinized saline
(40USPU/ml) starting at the left ventricle, and then with
4% paraformaldehyde in PBS for 10min. The formalin-fixed
aortas were excised and the adipose tissue surrounding
them was removed. They were cut open longitudinally,
permeabilized with PBS containing 0.1% Triton X-100, and
blocked with PBS containing 10% goat serum and 2.5%
Tween 20 for 30min. The aortas were incubated with
serum-free protein blocking buffer (#X0909; Dako
Denmark A/S, Glostrup, Denmark) for 30min, followed
by overnight incubation with rat antivascular endothelial-
cadherin (VE-cadherin) (7mg/ml) in antibody diluent
buffer (#S0809; Dako Denmark A/S). After a PBS rinse,
antirat IgG (1 : 1000 dilution) (Alexa Fluor 488; Invitrogen,
Carlsbad, California, USA) was applied for 1 h at room
temperature (16–25 8C). The samples were analyzed with
an A1R laser scanning confocal microscope (Nikon Instech
Co. Ltd., Tokyo, Japan). Ten to 15 optical sections were
collected at 0.3–0.5-mm increments. A z-stack of sections
was also obtained, consisting of4-mm-thick sections from
the luminal surface.
Vascular permeability
Ten-week-old mice either untreated or treated with 10mg/
kg per day L-NAME for 3 weeks were injected with 100ml
Evans blue (1% solution in PBS) via the tail vein 30min
before euthanasia. They were then transcardially perfused
with heparinized PBS to remove intravascular dye. The
gross coloring of the isolated aortas was observed. The
aortas were then flash-frozen and sectioned into 10-mm
slices. Evans blue dye extravasation was observed under a
fluorescence microscope (ECLIPSE Ti-U, Nikon, Tokyo,
Japan).
Cell culture
Human aortic endothelial cells were purchased from
TaKaRa Bio Inc., Kusatsu, Shiga, Japan. They were cultured
in Endothelial Cell Growth Medium 2 (TaKaRa Bio Inc.).
After overnight serum starvation, passage four to eight cells
were treated either with pitavastatin (10 or 100 nmol/l), 2-
(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-
3-oxide sodium (carboxy-PTIO) (10 or 100 mmol/l)
(Dojindo Laboratories), or 1-hydroxy-2-oxo-3,3-bis(2-ami-
noethyl)-1-triazene (NOC18) (10 or 100mmol/l) (Dojindo
Laboratories) for 24 h. Cell lysates were subjected to west-
ern blotting as described in western blot section.
Western blot
The proteins from the mouse aortas and cultured cells were
analyzed by western blotting as described previously [15].
The antibodies detected eNOS (Cell Signaling Technology
Inc., Danvers, Massachusetts, USA), VE-cadherin (Cell Sig-
naling Technology Inc.), and b-actin (Santa Cruz Biotech-
nology, Inc., Dallas, Texas, USA), all at 1 : 1000 dilution.
Statistical analysis
Data are presented as means standard error. Statistical
analysis was performed using StatMate IV for Windows
(ATMS Co. Ltd., Tokyo, Japan). Normally distributed con-
tinuous variables for more than three groups were com-
pared with two-way analysis of variance. Two-group
comparisons were madewith Student’s t tests. Nonnormally
distributed continuous variables were compared with the
Kruskal–Wallis test. Other pairwise comparisons were
made with the Mann–Whitney U test. Nominal categorical
data between groups were compared with the x2-test
or Fisher’s exact test where appropriate. For all statistical
tests, P less than 0.05 and 0.001 were considered to
indicate significant and highly significant differences,
respectively.
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Analysis of the Japanese Adverse Drug Event
Report database
Adverse event data recorded in the Japanese Adverse Drug
Event Report (JADER) database from April 2004 until April
2015 were analyzed. They were obtained from the Phar-
maceuticals and Medical Devices Agency (http://www.
pmda.go.jp). The JADER database structure complies with
the international safety reporting guidelines of the Interna-
tional Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use
(ICH E2B). The database consists of patient demographic
information (demo), drug information (drug), adverse
events (reac), and primary illness (hist). The JADER data-
base does not include case report identification codes
(A1.11). Therefore, no data cleaning was required. The
‘Drug’ file (drug information) contains the role code
assigned to each drug, namely suspected drug, interacting
drug, and concomitant drug. In this study, only the records
for suspected drugs were analyzed.
The drug class selected for this investigation was the
statins (atorvastatin, fluvastatin, pitavastatin, pravastatin,
rosuvastatin, and simvastatin). All reported adverse events
of interest (i.e., aortic dissection) were defined as ‘cases’
and all other reported adverse events were designated
‘noncases.’ The adverse event risk was evaluated with
the reporting odds ratio (ROR) calculated using a case/
noncase method [16,17]. A 2 2 contingency table was
prepared and used as the framework for the analysis
(Supplementary Table 1, http://links.lww.com/HJH/A991).
The effects on aortic dissection of combining statins with the
suspected drug were analyzed. At least three cases were
reported, and the lower limit of the 95% confidence interval
(CI) of the ROR was more than 1.
RESULTS
Administration of Nv-nitro-L-arginine methyl
ester to the angiotensin IIþ
b-aminopropionitrile aortic aneurysm model
triggered the onset of aortic dissection
L-NAME administration started 3 weeks before Ang
IIþBAPN was used to establish an aortic aneurysm model
(western blot section). Ang IIþBAPN treatments were
continued for 6 weeks to investigate the incidence and
survival rate of aortic dissection. The low-dose (10mg/kg
per day) L-NAME changed neither body weight nor SBP
relative to that of the AB group (Fig. 1a and b). A Kaplan–
Meier analysis revealed no significant difference between
the AB and L-LAB groups in terms of overall survival rate.
The incidence of death from aortic rupture or dissection in
the L-LAB group increased within 1 week after treatment
with Ang IIþBAPN (Fig. 1c). The L-LAB group showed
significantly higher incidences of aortic dissection [44% (11/
25); P< 0.01] and rupture [36% (9/25); P< 0.05] than did the
AB group [8 (4/51) and 16% (8/51), respectively] after 6
weeks of treatment (Table 1).
FIGURE 1 Effects of Nv-nitro-L-arginine methyl ester addition to aneurysm model. Week 0 or Day 0 indicates starting time of angiotensin IIþb-aminopropionitrile loading.
Mice were monitored until Week 6. Body weight (a) and SBP (b) are expressed as means standard error (open circle: AB group; black square: L-LAB group). Survival rates
were calculated by the Kaplan–Meier method (c). Values were statistically analyzed using Student’s t test (a and b) or the generalized Wilcoxon signed rank test (c).
n¼19–51 for each group. P<0.05, P<0.01 vs. AB group. AB, Ang IIþBAPN-treated group; L-LAB, 10mg/kg per day L-NAME in Ang IIþBAPN-treated group.
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The Japanese Adverse Drug Event Report
database showed a relatively lower incidence
of aortic dissection with statin administration
The JADER database enables us to find candidate drugs that
can prevent aortic dissection during drug therapy. To
determine whether statins decreased the incidence of
drug-induced aortic dissection, we used the JADER data-
base to analyze the effect of combining statins with the
candidate drug.
Forty-four candidate drugs for aortic dissection therapy
were selected from the JADER database. For each drug, at
least three caseswere reportedwith a lower limit of the 95%
CI for ROR more than 1 (Supplementary Table 2, http://
links.lww.com/HJH/A991). The incidence rates were com-
pared with or without the concomitant use of pitavastatin
or at least one other statin. As shown in Table 2, the
incidences of aortic dissection with and without pitavas-
tatin coadministration were 0.06 and 0.11%, respectively.
The odds ratio (OR) was 0.52 (95% CI, 0.07–3.72;
P¼ 0.5148). Coadministration with any statin decreased
the incidence to 0.04%. In contrast, the incidence was
0.12% without the use of statins (OR¼ 0.30; 95% CI,
0.13–0.69; P¼ 0.0043). Therefore, there was a significant
decrease in the incidence of aortic dissection with
statin administration.
Pitavastatin prevented the incidence of aortic
dissection in LAB mice
To estimate whether LAB-induced aortic dissection in mice
was useful for evaluating drug efficacy, we examined the
effects of pitavastatin on aortic dissection. Representative
photomicrographs of the overall appearance and EVG
staining of the aortas are shown in Fig. 2a and b, respec-
tively. Photomicrograph measurements indicated that pit-
avastatin inhibited increases in the maximum diameters of
the thoracic and abdominal aortas of the L-LABmice (Fig. 2c
and d). The incidence of aortic dissection increased to
similar levels in both the L-LAB (70%, 7/10) and H-LAB
(62%, 8/13) groups. Pitavastatin administration delayed the
onset of aortic dissection in both the L-LAB (18%, 2/11) and
H-LAB (14%, 2/14) groups to levels comparable with that of
the AB group (Table 3). The degree of medial elastic fiber
disruption was quantified by EVG staining (Fig. 2b). The
L-LAB and H-LAB groups presented with more elastic fiber
disruption than the AB group did. Pitavastatin reduced
medial elastic fiber disruption to the level of the AB group
(Fig. 2e).
Figure 2g shows that 3-week administration of 100mg/
kg per day L-NAME without Ang II loading elevated SBP.
However, the blood pressures (BPs) in all groups, except
for the control, were similar after Ang II loading. Therefore,
pitavastatin may not have reduced the incidence of aortic
dissection by lowering BP.
Inflammatory responses were investigated in the LAB
model. The administration of L-NAME to AB mice increased
the expression of the CD68 and F4/80 genes (Fig. 3a and b).
These are markers of macrophages that had infiltrated the
vascular walls, which were also observed by Mac-2 immu-
nostaining (Fig. 3c). These increase in macrophage infiltra-
tion were suppressed by pitavastatin treatment in the L-LAB
model. Pitavastatin also significantly suppressed the upre-
gulation of other proinflammatory genes in the aortas of
the L-LAB model, including TNF-a, MCP-1, and VCAM-1
(Fig. 3d–f).
Nv-nitro-L-arginine methyl ester pretreatment
for 3 weeks induced endothelial cell injury
To determine whether pitavastatin attenuates L-NAME-
induced endothelial dysfunction, mice were either
untreated or subjected to L-NAMEþpitavastatin treatment
for 3 weeks before starting AB administration. The admin-
istration of L-NAME for 3 weeks decreased aortic eNOS
protein expression (Fig. 4a) and decreased NOx produc-
tion. NOx significantly increased in response to pitavastatin
administration (Fig. 4b). DHE staining revealed that oxida-
tive stress was increased by the administration of 10 or
100mg/kg per day L-NAME and was suppressed by pita-
vastatin (Fig. 4c and d).
It was recently reported that the expression of VE-cad-
herin modulates vascular permeability with NO [18]. En-
face staining and western blotting revealed that VE-cad-
herin protein expression was decreased in the aortas of
mice treated with L-NAME (Fig. 5a and b). Evans blue dye
leakage showed that L-NAME treatment induced vascular
hyperpermeability (Fig. 5c and d), possibly impairing the
integrity of endothelial cell junctions.
TABLE 1. Incidences of aneurysm, dissection, and rupture after 6
weeks observation or at the time of death
Control, n (%) AB, n (%) L-LAB, n (%)
TAA 0/19 (0) 19/51 (37) 13/25 (52)
AAA 0/19 (0) 28/51 (55) 19/25 (76)
AD 0/19 (0) 4/51 (8) 11/25 (44)
Rupture 0/19 (0) 8/51 (16) 9/25 (36)
The incidence of TAA, AAA, AD, and rupture were shown. Values are shown as n (%).
Data are statistically analyzed by chi-squared test. AAA, abdominal aortic aneurysm; AB,
Ang IIþBAPN treated group; AD, aortic dissection; L-LAB, 10mg/kg per day of
L-NAMEþAng IIþBAPN treated group; TAA, thoracic aortic aneurysm.
P<0.01 vs. AB group.
P<0.05.
TABLE 2. Decrease in the occurrence of suspected drug-induced aortic dissection by drug A in the Japanese Adverse Drug Event Report
database
Drug A
Cases without
drug A, n (%)
Cases with
drug A, n (%)
Odds ratio
(95% CI) P
Pitavastatin 118/109966 (0.11) 1/1792 (0.06) 0.52 (0.07–3.72) 0.5148
All statins 113/95090 (0.12) 6/16668 (0.04) 0.30 (0.13–0.69) 0.0043
CI, confidence interval.
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FIGURE 2 Effect of pitavastatin on aortic dissection model (LAB). Representative images of gross aortas (a; bar: 0.5mm) and Elastica van Gieson’s staining (b; bar: 0.5mm).
Diameters of thoracic aortas (c) and abdominal aortas (d) were measured. Numbers of disrupted elastic fibers observed with Elastica van Gieson’s staining (e). SBP was
monitored from the onset of Nv-nitro-L-arginine methyl ester administration until 1 week after angiotensin IIþb-aminopropionitrile loading (f). n¼5–11. Values were
analyzed using two-way analysis of variance for repeated measures (c–f). P<0.05, P<0.01 vs. control. L-LAB, LAB group treated with lower L-NAME dose (10mg/kg
per day); H-LAB, LAB group treated with higher L-NAME dose (100mg/kg per day).
TABLE 3. Incidence of aortic dissection and rupture at Day 7 after the initiation of angiotensin IIþb-aminopropionitrile loading
AD, n (%) Rupture, n (%)
AB 2/10 (20) 1/10 (10)
L-LAB 7/10 (70) 2/10 (20)
H-LAB 8/13 (62) 3/13 (23)
L-LABþ Pita 2/11 (18) 0/11 (0)
H-LABþ Pita 2/14 (14) 1/14 (7)
Values are shown as n (%). Data are statistically analyzed by chi-squared test. AB, Ang IIþBAPN treated group; H-LAB, 100mg/kg per day of L-NAMEþAng IIþBAPN treated group; L-
LAB, 10mg/kg per day of L-NAMEþAng IIþ BAPN treated group; Pita, pitavastatin.
P<0.05 vs. without pitavastatin treatment.
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To verify whether NO modulates VE-cadherin expres-
sion, cultured endothelial cells were exposed either to the
NO scavenger, carboxy-PTIO, or to the NO donor, NOC18.
NO production varied directly with VE-cadherin expression
and vice versa (Fig. 5e). Pitavastatin increased eNOS
expression in cultured endothelial cells. This observation
corroborated those of earlier studies [18]. VE-cadherin
protein expression increased in response to pitavastatin
FIGURE 3 Effects of pitavastatin on aortic inflammatory responses. Graphs show mRNA expressions of aortic inflammatory markers CD68 (a), F4/80 (b), TNF-a (d),
and monocyte chemoattractant protein-1 (e). n¼5. Values are fold increases relative to the average of the control and are expressed as means standard error. Two-way
analysis of variance for repeated measures was performed along with Bonferroni’s post-hoc tests. P<0.01. Panels (c) and (f) show representative images of Mac-2 (c) and
vascular cell adhesion molecule-1 (f) expressions. Arrowheads point to positive staining. ‘L’¼ lumen side. Bar: 0.1mm.
Drug efficacy against aortic dissection
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treatment (Fig. 5f and g). Pitavastatin may attenuate endo-
thelial cell junction failure by increasing eNOS and VE-
cadherin expression.
DISCUSSION
Several investigators have attempted to establish an animal
model in which a high rate of aortic dissection could be
induced. The most successful to date has been a mouse
model with BAPN/Ang II [19]. In earlier studies, BAPN was
administered at higher doses and for longer durations than
in our study, causing acute aortic dissection in 100% of the
mice within 24 h of the start of Ang II loading. In previous
models, aortic dissection was almost completely sup-
pressed in matrix metalloproteinase-9-deficient mice [19].
Therefore, the aortic dissection induced in earlier models
may have been the result of medial fragility and degrada-
tion. In fact, aortic dissection is known to occur in Marfan
FIGURE 4 Effects of pitavastatin on oxidative stress in aortas. Aortic endothelial nitric oxide synthase protein expression (a) and nitrite/nitrate (NOx) production (b) after
3 weeks treatment with Nv-nitro-L-arginine methyl ester (10mg/kg per day) were determined by western blotting and Griess method, respectively. Oxidative stress was
estimated by dihydroethidium staining. (c) Representative images; bar: 0.2mm. (d) Quantified dihydroethidium fluorescence. n¼4–7. Values are fold increases relative
to the average of the control and are expressed as means standard error. Two-way analysis of variance for repeated measures was performed along with Bonferroni’s
post-hoc tests. P<0.05, P<0.01.
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syndrome and other connective tissue disorders. However,
we deemed it necessary to develop an alternative animal
model simulating complications of metabolic syndrome,
aging, and other disorders rather than specific genetic
conditions. Therefore, we administered BAPN at a dose
just high enough to induce aneurysm. We added L-NAME
pretreatment instead of increasing BAPN dose. L-NAME was
originally used in hypertension models. Nevertheless, it has
been reported to cause endothelial dysfunction by sup-
pressing NO independently of hypertension [20,21]. NO is
essential for maintaining endothelial functions, such as
vasodilatation, vascular regeneration, inhibition of smooth
FIGURE 5 Nv-Nitro-L-arginine methyl ester-impaired mouse aortic endothelial cell junctions. Mice were treated with or without 100mg/kg per day Nv-nitro-L-arginine
methyl ester for 3 weeks. Aortas were subjected to en-face staining for vascular endothelialcadherin (a, green; bar: 50mm) or western blotting [(b1) representative blots
and (b2) quantified intensity]. Evans blue stain leakage was observed in mice treated with or without 100mg/kg per day Nv-nitro-L-arginine methyl ester for 3 weeks [(c)
low magnification pictures; bar: 1mm, (d1) Evans blue fluorescence; bar: 0.1mm, and (d2) quantified fluorescence intensity]. Vascular endothelialcadherin expression in
cultured endothelial cells measured by western blotting. Human aortic endothelial cells (e) treated with either carboxy-PTIO or NOC18 for 48 h. Panel (e1) shows
representative blots. Panel (e2) shows intensity. Human aortic endothelial cells were also stimulated with pitavastatin for 48 h. Protein expressions of endothelial nitric oxide
synthase and vascular endothelialcadherin were analyzed by western blotting. Representative bands (f) and quantified intensity (g) are shown. n¼4–8. Values are fold
increases relative to the average of the control and are expressed as means standard error. Two-way ANOVA for repeated measures was performed along with
Bonferroni’s post-hoc tests. P<0.05, P<0.01 vs. control.
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muscle cell proliferation and migration, platelet adherence,
and leukocyte chemotaxis [22,23]. Therefore, L-NAME-
induced NO suppression causes severe endothelial dys-
function and damage [24]. Even low doses of L-NAME
increased inflammation and hyperpermeability leading to
the early onset of aortic dissection without a significant
elevation in BP relative to the AB group. L-NAME-induced
endothelial dysfunction may trigger aortic dissection
regardless of the impairment of endothelium-dependent
vasodilatation. Our model also showed isolated endothelial
dysfunction without significant SBP elevation. SBP rose
soon after the initiation of Ang II treatment (Fig. 1). Under
L-NAME treatment, aortic dissection occurred simulta-
neously. These results suggest that BP increase is necessary
to trigger the onset of both aortic dissection and aneurysm.
However, endothelial dysfunction may be the link between
these two events.
Several studies demonstrated that statins prevent cardio-
vascular diseases by protecting endothelia [25]. Recently,
we reported that pitavastatin protects against acute cardiac
allograft rejection by activating endothelial extracellular-
signal-regulated kinase 5 [10]. As shown in Figs. 2 and 3,
pitavastatin may also prevent the onset of aortic dissection,
medial degradation, and inflammation. In the present
study, however, pitavastatin did not lower SBP elevation
induced by high L-NAME doses, despite increasing eNOS
expression and NOx production. Perez-Guerrero et al. [26]
showed that simvastatin restored NOx production that had
been inhibited by L-NAME but it did not lower SBP. It has
been proposed that deficient eNOS-dependent vascular
relaxation accounts for the L-NAME-induced hypertension
model. According to our report and several others, eNOS
dysfunction and NO deficiency alone may not fully explain
L-NAME-induced or endothelial dysfunction-dependent
hypertension [10,24–26]. Further studies are needed to
elucidate the roles of eNOS-NO and the endothelium in
BP regulation. Nevertheless, we can assume that the pro-
tective effects of statins against cardiovascular disease are
mediated by increases in NO, independent of BP reduction.
It has been reported that tight junctions and VE-cadherin
localization, phosphorylation, and expression play impor-
tant roles in vascular endothelial permeability [27,28]. In our
LAB model, VE-cadherin expression was diminished and
vascular leakage occurred (Fig. 5). It was suggested that a
possible mechanism for the protective effect of statins
against aortic dissection is their impact on endothelial
cell–cell junctions and changes in vascular permeability
(Fig. 5). Recently, Suzuki et al. [29] reported that pitavastatin
mitigates tight junction protein dysfunction in endothelial
cells. Berry et al. [30] reported a correlation between inter-
cellular junctions and aortic dissection. However, the rele-
vance of this association is not yet fully understood.
However, it may partially account for the mechanism by
which pitavastatin inhibited aortic dissection onset in
our model.
JADER is a large database of adverse events and useful
tools for correlating preventive drug use with drug-induced
adverse events [16]. We found 44 drugs in JADER associated
with an increased incidence of aortic dissection. We also
found that combining these drugs with statins significantly
decreased the occurrence of adverse events related to aortic
dissection (Table 2 and Supplementary Table 2, http://
links.lww.com/HJH/A991). These clinical data strongly
support the findings of pharmacological experiments
in vivo and in vitro.
In the present study, we established a novel murine
model for aortic dissection. In LAB mice, L-NAME induced
endothelial dysfunction. Compared with that of the other
groups, LAB presented with more severe aortic inflamma-
tion, medial degradation, and hyperpermeability. In LAB
mice, pitavastatin treatment decreased the incidence of
aortic dissection and death from aortic rupture. It is
believed that pitavastatin accomplished this by decreasing
reactive oxygen species and increasing NOx production
and by upregulating eNOS and VE-cadherin expression.
Moreover, JADER database mining suggested that pitavas-
tatin treatment clinically prevents aortic dissection.
Our findings expand the understanding of aortic dissec-
tion. First, endothelial dysfunction is key in elucidating the
pathogenesis of aortic dissection onset. Second, our novel
aortic dissection model does not involve genetically engi-
neered mice and may help identify the molecules and
mechanisms by which the endothelium and medial layer
contribute to the onset of this condition. Finally, this mouse
model, whether alone or in combination with database
analyses, could evaluate drug efficacy for aortic dissection
treatment or prevention.
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